Progenics Follow Verify

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics has two commercial products, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.; and AZEDRA, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.

http://www.progenics.com
Type	Public
Founded	1988
Headquarters	New York, New York
Number of employees	51-200 employees

Top 5 Recent Tweets

Date	Author	Comment
July 28, 2022	CureNETs	If you missed our 2022 KNOW YOUR NETs Conference you can stream the entire conference here https://t.co/knSF6AXzLa… https://t.co/3qTUNkLauG
July 28, 2022	ProgenicsCB	Unique Banking Technique & Storage Equipment All of our equipment meet the highest quality standards.… https://t.co/fMi86zQlMn
July 26, 2022	urotoday	Tumor Board reviewing locally adv pT3N1M0 #ProstateCancer. @CaPsurvivorship is joined by Andrei Iagaru, @geoffsonn… https://t.co/ABRm2TsmqS

Top 5 Lifetime News Headlines

Top Authors

• Cherry Ann Baluyut
• Chithma Kalansuriya
• Afaf Abdallah
• View all authors

Verification history

• 1,078 days ago


• 1,349 days ago


• 1,349 days ago


• View all verifications